Valacyclovir Hydrochloride/Celecoxib

盐酸伐昔洛韦/塞来昔布

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameValacyclovir Hydrochloride/Celecoxib
Drug Alias NameCelecoxib/valacyclovirIMC-2
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman herpesvirus 1 DNA polymerase inhibitorsHuman herpesvirus 5 DNA polymerase inhibitorsCyclooxygenase-2 inhibitors
TargetsHuman herpesvirus 1 DNA polymeraseHuman herpesvirus 5 DNA polymeraseCyclooxygenase-2
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeHerpesviridae Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Valacyclovir HydrochlorideCelecoxib
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVirios Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPRIDCor Therapeutics LLCVirios Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromeHerpesviridae Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A